Efficacy, Tolerability, and Safety of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1‐RA) in Kidney Transplant Recipients With Diabetes
Well-selected post-kidney transplant participants demonstrated good tolerance for GLP-1RA. Participants who took GLP1-RA had better glycemic control, more weight loss, a decrease in daily insulin requirements, better preservation of kidney function, and reduced proteinuria 12 months after initiation of GLP1-RA compared to those who did not. GLP1-RA did not alter tacrolimus levels or doses.
Authors
- Gaurav Agarwal (ORCID: https://orcid.org/0000-0003-4194-2670)
- Henry Zelada (ORCID: https://orcid.org/0000-0002-8159-0625)
- Mario Campana (ORCID: https://orcid.org/0000-0002-2151-4110)
- Orlando M. Gutiérrez (ORCID: https://orcid.org/0000-0001-6593-3571)
- Vineeta Kumar (ORCID: https://orcid.org/0000-0002-4271-463X)
- Kosuke Kawai
- David T. Redden (ORCID: https://orcid.org/0000-0002-1016-272X)
Institutions
- Rush University Medical Center (US)
- University of California, Los Angeles (US)
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1111/ctr.70144
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88